405 related articles for article (PubMed ID: 20145621)
1. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells.
Shinto O; Yashiro M; Kawajiri H; Shimizu K; Shimizu T; Miwa A; Hirakawa K
Br J Cancer; 2010 Mar; 102(5):844-51. PubMed ID: 20145621
[TBL] [Abstract][Full Text] [Related]
2. Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice.
Shinto O; Yashiro M; Kawajiri H; Shimizu K; Shimizu T; Miwa A; Hirakawa K
Cancer Sci; 2010 Aug; 101(8):1846-52. PubMed ID: 20518790
[TBL] [Abstract][Full Text] [Related]
3. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
4. A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma.
Kawajiri H; Yashiro M; Shinto O; Nakamura K; Tendo M; Takemura S; Node M; Hamashima Y; Kajimoto T; Sawada T; Ohira M; Hirakawa K
Clin Cancer Res; 2008 May; 14(9):2850-60. PubMed ID: 18451253
[TBL] [Abstract][Full Text] [Related]
5. Berberine Suppresses EMT in Liver and Gastric Carcinoma Cells through Combination with TGF
Du H; Gu J; Peng Q; Wang X; Liu L; Shu X; He Q; Tan Y
Oxid Med Cell Longev; 2021; 2021():2337818. PubMed ID: 34712379
[TBL] [Abstract][Full Text] [Related]
6. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
Ehata S; Hanyu A; Fujime M; Katsuno Y; Fukunaga E; Goto K; Ishikawa Y; Nomura K; Yokoo H; Shimizu T; Ogata E; Miyazono K; Shimizu K; Imamura T
Cancer Sci; 2007 Jan; 98(1):127-33. PubMed ID: 17129361
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type IIB receptor.
Persson U; Souchelnytskyi S; Franzén P; Miyazono K; ten Dijke P; Heldin CH
J Biol Chem; 1997 Aug; 272(34):21187-94. PubMed ID: 9261125
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of transforming growth factor-beta signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGF beta type I receptor kinase.
Yakymovych I; Engström U; Grimsby S; Heldin CH; Souchelnytskyi S
Biochemistry; 2002 Sep; 41(36):11000-7. PubMed ID: 12206672
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Wendt MK; Schiemann WP
Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
[TBL] [Abstract][Full Text] [Related]
10. Curcumin inhibits transforming growth factor-β1-induced EMT via PPARγ pathway, not Smad pathway in renal tubular epithelial cells.
Li R; Wang Y; Liu Y; Chen Q; Fu W; Wang H; Cai H; Peng W; Zhang X
PLoS One; 2013; 8(3):e58848. PubMed ID: 23544048
[TBL] [Abstract][Full Text] [Related]
11. Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II.
Maeda M; Shintani Y; Wheelock MJ; Johnson KR
J Biol Chem; 2006 Jan; 281(1):59-68. PubMed ID: 16267045
[TBL] [Abstract][Full Text] [Related]
12. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
[TBL] [Abstract][Full Text] [Related]
13. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion.
Galliher AJ; Schiemann WP
Cancer Res; 2007 Apr; 67(8):3752-8. PubMed ID: 17440088
[TBL] [Abstract][Full Text] [Related]
14. Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-β signaling.
Norita R; Suzuki Y; Furutani Y; Takahashi K; Yoshimatsu Y; Podyma-Inoue KA; Watabe T; Sato Y
Cancer Sci; 2017 Mar; 108(3):419-426. PubMed ID: 28064471
[TBL] [Abstract][Full Text] [Related]
15. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Melisi D; Ishiyama S; Sclabas GM; Fleming JB; Xia Q; Tortora G; Abbruzzese JL; Chiao PJ
Mol Cancer Ther; 2008 Apr; 7(4):829-40. PubMed ID: 18413796
[TBL] [Abstract][Full Text] [Related]
16. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.
Nakao A; Imamura T; Souchelnytskyi S; Kawabata M; Ishisaki A; Oeda E; Tamaki K; Hanai J; Heldin CH; Miyazono K; ten Dijke P
EMBO J; 1997 Sep; 16(17):5353-62. PubMed ID: 9311995
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-β signaling.
Hasegawa T; Yashiro M; Nishii T; Matsuoka J; Fuyuhiro Y; Morisaki T; Fukuoka T; Shimizu K; Shimizu T; Miwa A; Hirakawa K
Int J Cancer; 2014 Apr; 134(8):1785-95. PubMed ID: 24155219
[TBL] [Abstract][Full Text] [Related]
18. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
Komuro A; Yashiro M; Iwata C; Morishita Y; Johansson E; Matsumoto Y; Watanabe A; Aburatani H; Miyoshi H; Kiyono K; Shirai YT; Suzuki HI; Hirakawa K; Kano MR; Miyazono K
J Natl Cancer Inst; 2009 Apr; 101(8):592-604. PubMed ID: 19351925
[TBL] [Abstract][Full Text] [Related]
19. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
20. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
Park CY; Kim DK; Sheen YY
Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
